Sareum Holdings (SAR)

 

SAR Share PerformanceMore

52 week high1.2750 16/02/17
52 week low0.7000 29/11/17
52 week change 0.0300 (3.66%)
4 week volume356,436,926 18/11/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Result of AGM

RNS Number: 3728Z Sareum Holdings PLC 14 December 2017 (AIM: SAR) 14 December 2017 Sareum Holdings plc ("Sareum" or "the Company") Results of AGM Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, advises that it held its Annual General Meeting today and all resolutions were duly passed. -Ends- For furth...

Sareum reports 'significant' year of progress

Sareum Holdings, a cancer drug discovery and development business, said it has seen a year of significant progress. Its lead...

AGM Statement

RNS Number: 2254Z Sareum Holdings PLC 14 December 2017 (AIM: SAR) 14 December 2017 Sareum Holdings plc ("Sareum" or "the Company") AGM Statement Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, will be holding its Annual General Meeting today, at 10:00 at the offices of Citigate Dewe Rogerson, 3 Londo...

Notice of AGM and Annual Report & Accounts

RNS Number: 8386W Sareum Holdings PLC 20 November 2017 (AIM: SAR) 20 November 2017 Sareum Holdings plc ("Sareum" or "the Company") Notice of AGM and Annual Report & Accounts Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, has notified its shareholders that its Annual General Meeting ("AGM") w...

Placing

RNS Number: 4679W Sareum Holdings PLC 14 November 2017 (AIM: SAR) 14 November 2017 Sareum Holdings plc ("Sareum" or "the Company") Placing Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces that it has raised 700,000, before expenses, through a placement via Hybridan LLP as agent of the Comp...

Sareum notes experiment progress

Sareum Holdings has noted that Sierra Oncology, the licence holder advancing a clinical cancer candidate Chk1 inhibitor, r...

Sierra Reports Preclinical Data for Chk1 Inhibitor

RNS Number: 0638V Sareum Holdings PLC 31 October 2017 (AIM: SAR) 31 October 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy - SRA737 demonstrates synergy with replication stress-inducing agents - - SRA737 plus gemci...

Sareum reports maiden profit of £400,000

Sareum, a cancer drug discovery and development company, made a maiden profit after tax on ordinary activities of 400...

Fundamental DataMore

P/E ratio42.5
EPS0.02
Dividend yield0 %

Latest discussion posts More

  • Re: Good progress & maiden profits

    http://uk.advfn.com/p.php?pid=chartscreenshotshow&u=CTcwOoFJTTlWkejW+geWUhtoFp3NOSgnWPFmM8wjkZQ= Posted this chart in October - been waiting for 0.75p entry price since then ...
    16-Nov-2017
    KALAN
  • Re: Another 200% up....

    Cornhill had this for a week .
    15-Nov-2017
    Ripley94
  • Re: Another 200% up....

    RNS placing @ 7p Share price dropped 14%...... to 7.5p to 8p. British Bulls were correct maybe does show in chart. Again Aim all about placings at a discount.
    14-Nov-2017
    Ripley94

Users' HoldingsMore

Users who hold Sareum Holdings also hold..

Codes & Symbols

ISINGB00B02RFS12
SymbolsSAR, LSE:SAR, SAR.L, SAR:LN, LON:SAR, XLON:SAR

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account